Opterion's OPT101 Clears Phase 1 in Peritoneal Dialysis, Advancing to Phase 2a GLOW Trial
核心洞察
Opterion Health reported positive first-in-human Phase 1 results for OPT101, a non-glucose-based osmotic solution for peritoneal dialysis, in patients with moderate to severe chronic kidney disease (搜索).
The SPARC study met all major endpoints covering safety, tolerability, pharmacokinetics and functional activity, with no serious adverse events or dose-limiting toxicities reported.
The highest OPT101 concentration produced the greatest mean fluid removal in both four-hour and eight-hour dwells, accompanied by sodium removal.
Opterion Health AG (搜索) reported positive results from SPARC, its first-in-human Phase 1 study of OPT101, an investigational non-glucose-based osmotic driver solution for peritoneal dialysis. The Swiss clinical-stage biotechnology company said the study achieved its objectives across all major endpoints, including safety, tolerability, pharmacokinetics and functional activity in patients with moderate to severe chronic kidney disease (搜索), supporting advancement of the program to Phase 2a.
SPARC Design and Endpoints
SPARC evaluated different concentrations of OPT101 in four-hour and eight-hour dwells in patients with moderate to severe chronic kidney disease (搜索). The study reported no serious adverse events, no treatment discontinuations due to adverse events, no dose interruptions, no concentration-limiting toxicities and no interruptions to dose escalation.
OPT101 demonstrated activity across all evaluated concentrations. The highest concentration produced the greatest mean fluid removal in both short and long dwells, accompanied by sodium removal. Fluid and sodium removal across both dwell settings underpins the company's positioning of OPT101 as a differentiated non-glucose-based approach to peritoneal dialysis.
"This marks an important value inflection point for our company," said Peter Reinemer, Chief Executive Officer of Opterion Health AG (搜索). "OPT101 has progressed from scientific promise to encouraging clinical evidence in patients. SPARC strengthens our confidence in the program and creates meaningful momentum in a very large therapeutic field that has seen limited innovation for more than three decades."
Investigator Perspective on the Unmet Need
Aivars Pētersons, Principal Investigator of the SPARC study, described the trial as a positive first clinical experience with OPT101 and said patients responded well. "Peritoneal dialysis offers patients greater independence, but current solutions still involve important limitations," Pētersons said. "A flexible, non-glucose-based option for both short and long dwells could address a clear unmet need and be a welcome innovation."
Peritoneal dialysis allows people with kidney failure (搜索) to receive life-sustaining treatment at home, but patients still rely heavily on glucose-based solutions that can contribute to metabolic complications, weight gain and damage to the peritoneal membrane over time, according to the company. Existing non-glucose alternatives cannot cover both short and long dwells, which limits treatment choice and adds complexity to an already demanding daily routine. Opterion states that no currently available solution offers the same intended combination of non-glucose-based treatment, concentration flexibility and use across both dwell settings.
Phase 2a GLOW Trial Planned
The Phase 2a GLOW trial is expected to evaluate repeated administration of OPT101, dose selection, broader dwell replacement and the agent's functional and metabolic differentiation in chronic kidney disease (搜索) patients.
"SPARC delivered the results we needed and provides a strong foundation for OPT101's next stage of development," said Maxim Voropaiev, Chief Medical Officer of Opterion Health AG (搜索). "The Phase 2a GLOW trial is expected to evaluate repeated use, optimize dose selection and assess OPT101 across more of the daily dialysis regimen, bringing us closer to demonstrating its functional and metabolic differentiation in this patient population."
Market Context
Peritoneal dialysis accounts for only around 12% of dialysis patients globally despite offering clinical and lifestyle advantages, according to Opterion. As rising rates of chronic kidney disease (搜索) and diabetes (搜索) increase pressure on healthcare systems, the company estimates the global PD market at approximately USD 11.5 billion in 2025, projected to reach USD 21.5 billion by 2034, a compound annual growth rate of approximately 7.2%.
OPT101 is the lead program of Opterion Health AG (搜索), which describes itself as advancing a novel non-glucose-based approach to peritoneal dialysis suitable for both short and long dwell use. The company said OPT101 has successfully completed Phase 1 clinical evaluation and is being developed to address longstanding limitations of conventional PD therapy, with the goal of expanding treatment choice and enabling more patients to benefit from home-based dialysis.